Bellerophon to present at the h.c. wainwright 23rd annual global investment conference

Warren, n.j., sept. 07, 2021 (globe newswire) -- bellerophon therapeutics, inc. (nasdaq: blph) (“bellerophon” or the “company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that fabian tenenbaum, chief executive officer, will present a corporate overview at the h.c. wainwright 23rd annual global investment conference, being held september 13-15, 2021.
BLPH Ratings Summary
BLPH Quant Ranking